New device AVELI tackles cellulite and fibrosis in liposuction patients

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing HDL between 18 and 60 years old. * Non-gender specific. * American Association of Anesthesiologist Risk Assessment (ASA) ≤ 2. * Body Mass Index (BMI) ≥20 and ≤ 32 kg/m2. * Patients with any degree of clinically evident cellulite in any body area. * Patients with prior liposuction procedures with any degree of fibrosis in any body area. * Patients undergoing additional procedures such as, but not limited to: Rhinoplasty, Mammaplasty, Mastopexy, mini tummy tuck, full tummy tuck, brachioplasty, thighplasty, fat grafting. The procedure could not be related to the treatment of fibrosis or cellulite. Exclusion Criteria: * Patients requiring SQ fat grafting for the amendment of any contour irregularity. * Patients requiring other devices/drugs for skin contraction and/or cellulite treatment for the next 6 months (RF, US, Enzymes, etc.). * Patients undergoing Face Lift procedures. * Patients with any history of abnormal scarring and/or hypertrophic scars and or keloids. * Patients with Caprini score ≥ 8. * Patients with past medical history of connective tissue disease with active disease and/or recent relapse. * Patients with past medical history thromboembolic disease or any other condition with an increased risk of coagulopathy (i.e., SLE, RA, APS). * Patients using aspirin or any anticoagulant within 14 days and 5 days prior to surgery, respectively. * Patients with a PMH of epilepsy or any epileptic syndrome and or vascular disease. * Patients with any chronic disease non-compliant with treatment or non-adequately controlled. * Positive pregnancy test or planning on getting pregnant in the next 6 months. * Patients with fever or any other symptoms/signs of infection. * Active smokers or chronic smokers with recent quit (≤ 4-8 weeks). * Patients with prothrombin time (PT) and/or activated partial thromboplastin time (aPTT) \>1.5 times baseline.